LON:AREC

Arecor Therapeutics Final Earnings Results & Report

Arecor Therapeutics logo
GBX 72 -4.00 (-5.26%)
As of 11/20/2026 09:56 AM Eastern

Arecor Therapeutics reported Final earnings on April 22, 2025. The company reported EPS of -GBX 0.31.

Earnings Announcement Details

Quarter
Final
Report Date
Time
Before Market Opens

Arecor Therapeutics EPS Results

Actual EPS
-GBX 0.31
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Arecor Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Arecor Therapeutics Final Earnings FAQ

Arecor Therapeutics (LON:AREC) reported earnings of -GBX 0.31 per share for Final. The report was announced on Tuesday, April 22, 2025.

Arecor Therapeutics Earnings Headlines

Arecor Therapeutics PLC
Every Starlink dish pays this stock
There's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.tc pixel
Patents for concentrated ultra-rapid insulins
Arecor Therapeutics adds patents as it eyes $3 billion US market
See More Arecor Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Arecor Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Arecor Therapeutics and other key companies, straight to your email.

About Arecor Therapeutics

Arecor Therapeutics (LON:AREC) (AIM: AREC) is a clinical-stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases. Lead product, AT278, is the only ultra-concentrated (500U/mL) ultra-rapid-acting insulin in development. Arecor has signed an initial strategic partnership with Sequel Med Tech, a leading automated insulin delivery (AID) system company to co-develop AT278 in combination with Sequel’s twiist™ AID system. Clinically de-risked, AT278 is designed to transform AID systems, addressing a multi-billion-dollar diabetes market. Arecor is also developing a novel oral delivery platform for peptides with GLP-1 receptor agonists its first validation target.

View Arecor Therapeutics Profile